14 January 2013 - GeoVax Labs, an Atlanta-based vaccine developer, has completed the enrolment of nine patients in a Phase 1/2 trial evaluating the safety, immunogenicity and ability of its DNA/MVA vaccine, the HIV/AIDS therapeutic vaccine, it was reported on Friday.

The study is aimed at assessing the safety and immunogenicity of the company’s vaccine in HIV-positive patients who can manage infections utilising oral HIV drug medication.

The trial covers a short period of drug-interruption to evaluate the vaccine’s ability to control the infection in the absence of continuing drug therapy, subsequent to vaccination.